Handelsbanken Fonder AB Purchases 3,000 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Handelsbanken Fonder AB grew its holdings in Blueprint Medicines Co. (NASDAQ:BPMC) by 19.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 18,651 shares of the biotechnology company’s stock after purchasing an additional 3,000 shares during the quarter. Handelsbanken Fonder AB’s holdings in Blueprint Medicines were worth $1,627,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of BPMC. Creative Planning boosted its position in shares of Blueprint Medicines by 6.8% in the 3rd quarter. Creative Planning now owns 13,194 shares of the biotechnology company’s stock worth $1,220,000 after purchasing an additional 843 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Blueprint Medicines by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,206 shares of the biotechnology company’s stock worth $297,000 after buying an additional 927 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Blueprint Medicines by 22.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,291 shares of the biotechnology company’s stock valued at $212,000 after acquiring an additional 422 shares during the last quarter. Pallas Capital Advisors LLC raised its position in shares of Blueprint Medicines by 3.2% in the 3rd quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company’s stock valued at $523,000 after acquiring an additional 176 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Blueprint Medicines by 65.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,183 shares of the biotechnology company’s stock valued at $1,127,000 after buying an additional 4,828 shares in the last quarter.

Insider Activity

In related news, CEO Kate Haviland sold 2,353 shares of the company’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $96.60, for a total transaction of $227,299.80. Following the completion of the sale, the chief executive officer now directly owns 150,824 shares in the company, valued at $14,569,598.40. This represents a 1.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Ariel Hurley sold 1,819 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $93.26, for a total value of $169,639.94. Following the transaction, the insider now directly owns 14,967 shares in the company, valued at $1,395,822.42. This trade represents a 10.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 47,577 shares of company stock worth $4,768,439. 4.21% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have issued reports on BPMC shares. Piper Sandler lifted their price target on Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Stephens reaffirmed an “overweight” rating and issued a $140.00 target price on shares of Blueprint Medicines in a research report on Thursday, January 2nd. JMP Securities reissued a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a research report on Friday, February 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $133.00 target price on shares of Blueprint Medicines in a research report on Thursday, February 13th. Finally, StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Saturday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $123.83.

Blueprint Medicines Stock Performance

Shares of BPMC opened at $91.33 on Wednesday. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The firm has a market cap of $5.84 billion, a PE ratio of -84.56 and a beta of 0.61. Blueprint Medicines Co. has a 1 year low of $80.68 and a 1 year high of $121.90. The stock’s fifty day moving average price is $99.38 and its two-hundred day moving average price is $94.42.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, equities research analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.